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Background: Two randomised controlled trials have found a higher risk of rhabdomyolysis in users of 80 mg
versus 20 mg simvastatin, but there is very limited information about the risk associated with other doses. We
undertook a nested case–control study, using routinely collected national health and drug dispensing data, to
estimate the relative and absolute risks of rhabdomyolysis resulting in hospital admission or death according
to simvastatin dose.
Methods and results: The underlying study cohort comprised all patients (n = 313,552) who initiated a new
episode of simvastatin use in New Zealand between 1 May 2005 and 31 December 2009. Cases (n = 29) were
patients with a diagnosis of rhabdomyolysis after cohort entry, conﬁrmed by hospital discharge letter or death
records. Ten controls, matched by year of birth and sex, were randomly selected from the study cohort using
risk set sampling. Current users of 40mg simvastatin daily were about ﬁve times as likely to develop rhabdomy-
olysis as those taking 20 mg; the adjusted odds ratio was 5.3 (95% CI 1.9–15.0). The absolute excess risk of
rhabdomyolysis associated with the use of 40 mg versus 20 mg was about 10 per 100,000 person-years; the
crude incidence rateswere 11.5 (95% CI 7.1–17.5) and 2.1 (95%CI 0.7–4.8) per 100,000person-years respectively.
Conclusions: These ﬁndings provide reassurance that the absolute risk of rhabdomyolysis in a general population
of simvastatin users is very low. Nonetheless, they also raise questions about the optimal simvastatin regimen to
maximise cardiovascular beneﬁts and minimise the risk of serious muscle injury.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The important role of statins in the prevention ofmajor cardiovascu-
lar events (coronary events, coronary revascularisation, and ischaemic
strokes) is well-established [1–5]. Along with evidence of additional
beneﬁt with intensive statin therapy, and the adoption of absolute car-
diovascular risk reduction approaches, this has led to the widespread
use of statins and the prescription of higher doses [5,6]. Muscle injury
is a rare, but potentially fatal, adverse effect of statin use [6]. In its
most severe form, rhabdomyolysis, release of myoglobin from damaged
muscle can lead to acute renal failure [6]. While the magnitude of the
risk appears to vary by drug, all statins have been associated with
adverse muscle events [6].liability and freedom from bias
itiative grant from the Health
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eland Ltd. This is an open access artIn June 2011, the US Food and Drug Administration issued prescrib-
ing advice regarding simvastatin dose and the risk of muscle injury [7].
In brief, it recommended that simvastatin 80 mg should not be pre-
scribed to patients starting simvastatin, or to patients currently taking
a lower dose of the drug, and its continued use should be restricted to
those patients who had taken 80 mg for at least 12 months without ev-
idence of muscle toxicity. This advice followed a review of preliminary
results from the Study of the Effectiveness of Additional Reductions in
Cholesterol and Homocysteine (SEARCH) trial, as well as data from
other randomised controlled trials, observational studies, and adverse
event reports. In the SEARCH trial, a randomised controlled trial of
80mg versus 20mg simvastatin daily in 12,064 survivors of myocardial
infarction, there were seven cases (0.1%) of rhabdomyolysis in the 80mg
group during amean follow-up of 6.7 years and none in the 20mg group
[8]. In Phase Z of the A to Z trial based on 4497 patients with recent acute
coronary syndrome, three (0.1%) participants taking 80 mg simvastatin
developed rhabdomyolysis during a median follow-up of 2.0 years,
while no cases were observed in the 20 mg group [9].
Information about the nature of any dose–response relationship as-
sociatedwith other doses of simvastatin is limited, as other trials involv-
ing at least one year of simvastatin therapy assessed the efﬁcacy and
safety of 20 mg [10] or 40 mg [11] daily in relation to placebo, oricle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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based on administrative data found a progressive increase in rhabdo-
myolysis incidence according to broad categories of simvastatin dose
(20–39, 40–79, and ≥80 mg daily) [13]. A more detailed exploration
of this relationship is warranted because clinical guidelines in some set-
tings (for example, national guidelines in the United Kingdom [UK] [14]
and New Zealand [15]) speciﬁcally recommend simvastatin as the ﬁrst-
line statin for the primary and secondary prevention of cardiovascular
events. We therefore undertook a population-based case–control
study nested within a large cohort of patients initiating simvastatin
use to estimate the relative and absolute risks of rhabdomyolysis in re-
lation to daily dose of simvastatin.
2. Methods
2.1. Data sources
The study was based on routinely collected health and drug dispensing data in New
Zealand. The Ministry of Health holds several national data collections, including the
Mortality Collection (all hospital and community deaths), the National Minimum Dataset
(hospital discharges from 1988), and the Cancer Registry [16]. Patient records in these
datasets all include a unique alpha-numeric identiﬁer, the National Health Index (NHI)
[17], and diagnoses are coded according to successive revisions of the International Classi-
ﬁcation of Diseases (ICD) [18]. The Ministry also holds the Pharmaceutical Collection
(Pharms), which contains the records of all claims by community-based pharmacists for
the dispensing of prescription drugs which are publicly funded (most medicines pre-
scribed in New Zealand) [19]. Since 2005, almost all pharmaceutical subsidy claims have
included an NHI and this has enabled the linkage of drug utilisation and health data.
2.2. Identiﬁcation of the study cohort
Ministry of Health staff searched the Pharms database to identify all patients who
were dispensed simvastatin (including simvastatin in combination with ezetimibe) at
least once between 1 January 2005 and 31 December 2009. For these patients, the
Ministry provided us with demographic information (date of birth, sex, ethnicity, and
NZDep06, an area-based measure of socio-economic position [20]) and details of the
following: all dispensings of simvastatin and other medicines (including subsequent
dispensings of other statins) between 2005 and 2009 (including dispensing date, medi-
cine name, administration route, strength of tablet or other unit dispensed, total number
of tablets or units to be taken daily, days' supply, and quantity dispensed), any hospital
admissions from 1988 onwards (including dates, principal and additional diagnoses, pro-
cedure and external cause codes), any cancer registrations, and any deaths. The date of the
ﬁrst dispensing of simvastatin from1 January 2005 onwardswas taken as the cohort entry
date.
All linkages using NHIs were done in-house by the Ministry and the data for all pa-
tients, except those initially identiﬁed as potential cases (see below), were supplied
with a unique study identiﬁcation number rather than an NHI to preserve anonymity.
Any linked records for which the dispensing information and health data clearly did not
refer to the same person (for example, peoplewho implausibly receivedmedicines before
their supposed date of birth or after their supposed date of death) were excluded. In this
circumstance, the NHI recorded in the Pharms dispensing data (the only personal identi-
ﬁer recorded in the Pharms database) must have been incorrect.
As randomised controlled trial data suggest that the risk of adverse muscle events is
highest in the ﬁrst 12 months of an episode of statin use [8], we followed patients from
the initiation of therapy. We therefore excluded all patients who were dispensed simva-
statin in the 120 day period between 1 January and 30 April 2005 to avoid the inclusion
of patients who were continuing an episode of use begun before 1 January 2005
(a maximum supply of 90 days can be dispensed at one time in New Zealand).
2.3. Nested case–control study
2.3.1. Identiﬁcation of cases and selection of controls from study cohort
We carried out all steps in the identiﬁcation of potential cases and the selection of
controls without knowledge of the dose of simvastatin they had been prescribed.
2.3.1.1. Cases. The identiﬁcation of eligible cases occurred in several stages. First, the
Ministry of Health searched hospital discharge and mortality data to identify all patients
with a diagnosis coded either to the acquired myopathy ICD-10-AM-I (International Sta-
tistical Classiﬁcation of Diseases and Related Health Problems Tenth Revision, Australian
Modiﬁcation) [18] rubrics under which rhabdomyolysis may be classiﬁed, or to
myoglobinuria or acute renal failure rubrics, after initiating simvastatin use (Appendix
1). These were the patients for whom NHIs were provided. As the speciﬁcity of this
broad search strategy was inevitably low, we then applied further diagnostic criteria (Ap-
pendix 2) which were adapted from an ICD-9 based algorithm developed by others [21].
For patients who met these criteria, we then sought copies of hospital discharge letters,
necropsy reports, and any other death records in order to validate the diagnosis of rhabdo-
myolysis. Two of us (LP, CP) independently reviewed the available information andclassiﬁed patients as rhabdomyolysis cases if they met the following standard criteria:
[6] muscle symptoms (pain, tenderness, or weakness) accompanied by a serum creatine
kinase (CK) concentration N40 times the upper limit of the normal range and/or evidence
of renal damage (acute renal failure or worsened renal function).
For a secondary analysis, we also identiﬁed cases of myopathy and classiﬁed these as
deﬁnite or possible. Deﬁnite myopathy cases were patients with muscle symptoms and a
CK concentration 10–40 times theupper limit of normal [6]. Possiblemyopathy caseswere
thosewhohad a physician-recordeddiagnosis of acutemyopathy and an unrecorded, nor-
mal, or elevated CK concentration up to 10 times the upper limit of normal. Patients with
chronic myopathies which had been attributed to clearly deﬁned causes (such as long-
term steroid use, alcoholism, inherited myopathies) were not included as cases.
The date of diagnosis was taken as an index date.
2.3.1.2. Controls. For each case we randomly selected 10 controls, matched by year of birth
and sex, using risk set sampling [22] from the study cohort. Hence controls were cohort
members, and at risk of becoming a case themselves, on the index date of their matched
case.
2.3.2. Simvastatin exposure
Cases and controlswere deﬁned as current users of simvastatin if their dispensed sup-
ply extended into the 30 day period before the index date. Current users were further
categorised according to the total daily dose (in milligrams, mg) of simvastatin and
whether it was taken alone or in combination with ezetimibe. Cases and controls whose
dispensed supply of simvastatin extended to within 31–90 days before the index date
were deﬁned as recent users, while those whose supply terminated N90 days before the
index date were classiﬁed as past users.
For a very small proportion ofﬁnal dispensings before the index date (5.7%), values for
the “days' supply” and “number of tablets to be taken daily” variables were missing. We
developed rules to derive values for these variables (based on the quantity of tablets dis-
pensed) in order to determine user status and total daily dose. The validity of these rules
was conﬁrmed in a separate exercise based on patients who did not have missing values.
We also developed rules to dealwith situations inwhichmore thanone dispensing of sim-
vastatin occurred on the same date (1.9% of ﬁnal dispensings before the index date). For
example, patients who received a 90 day supply of simvastatin 20 mg daily and a 90 day
supply of 40mg daily on the same day were classiﬁed as receiving a 90 day supply of sim-
vastatin 60 mg daily. The development and application of all rules were undertaken with
the case/control status of study members masked.
2.3.3. Other key variables
The following factors were identiﬁed a priori as potential confounders and relevant
data were extracted from the health and dispensing records of cases and their age and
sex-matched controls: demographic characteristics (ethnicity, NZDep06 score), a history
before the index date of admissions with co-morbidities postulated to increase the risk
of rhabdomyolysis (including hypothyroidism, Type 1 diabetes, Type 2 diabetes, renal im-
pairment or failure, hepatic impairment or failure, myocardial infarction, excess alcohol
consumption, illicit drug use, overdose, major trauma, hyperthermia, hypothermia, ex-
treme exertion, and status epilepticus) [6,23,24], and the use of other drugs before the
index date (excluding topical preparations) known or suspected to cause muscle injury
or interactwith statins (including amiodarone, azol antifungals, calcium channel blockers,
cyclosporin, danazol, ﬁbrates, fusidic acid, macrolide antibiotics, nefazodone, nicotinic
acid, protease inhibitors, thiazolidinediones/glitazones, and warfarin) [6,23,25]. Informa-
tion derived from the admission, or death records, in which a case was diagnosed with
rhabdomyolysis or myopathy was not used.
2.3.4. Statistical methods
Weused conditional logistic regression to calculate odds ratios and 95% conﬁdence in-
tervals (95% CIs). The primary analysis explored the risk of rhabdomyolysis in current
users of simvastatin according to dose; current users of 20 mg simvastatin were the refer-
ence category. In a secondary analysis, we examined the risk of rhabdomyolysis or myop-
athy, combined, by dose of simvastatin. We also estimated the risks of rhabdomyolysis,
and of rhabdomyolysis or myopathy, by equipotent LDL-lowering doses [7] of simvastatin
or atorvastatin (the only other statin to which cases or controls switched following their
initial use of simvastatin). Potential confounding was explored by adding variables one
by one to the regression; variables which changed the odds ratios by 10% or more were
retained in themodels [26]. We also attempted to explore effect modiﬁcation (multiplica-
tive interaction) by concomitant use of amiodarone, calcium channel blockers, cyclospor-
in, macrolide antibiotics, andwarfarin inmodels with interaction terms. All analyseswere
undertaken using Stata version 12.
2.4. Estimation of incidence rates
The simvastatin dispensing data of each member of the study cohort were
summarised into continuous episodes of use of the same total daily dose of simvastatin
using the same approach as another study of rhabdomyolysis incidence [27]. A continuous
episodewas one inwhich the elapsed time between the end date of one dispensed supply
and the start date of the next was 30 days or less; 30 days were added to the end date of
the ﬁnal dispensing in an episode of use. Episodes were censored at the earliest of any of
the following: another dose of simvastatin was dispensed, another statin was dispensed,
the patient died, the study period ended (31 December 2009), or the index date was
reached (if a case). The durations of episodes were then added together to obtain total
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were estimated by dividing the number of cases in a particular category of exposure by the
person-years of follow-up for that category. The Poisson distributionwas used to calculate
95% CIs for the rates.
2.5. Review of spontaneous reports of adverse reactions
Following the completion of the nested case–control study and estimation of inci-
dence rates, we searched the national adverse reactions database at the Centre for Adverse
ReactionsMonitoring (CARM) [28] for reports in statin users of rhabdomyolysis or myop-
athywhich resulted inhospital admission or death during the study period. Thepurpose of
this reviewwas two-fold: to determinewhat proportion of our cases had been reported to
CARM (identiﬁed using NHIs) and, conversely, to ascertain whether there were any re-
ported rhabdomyolysis and myopathy cases who met our eligibility criteria but were
not identiﬁed and included in our study.
2.6. Ethical approval
The study was approved by the New Zealand Multi-region Ethics Committee (refer-
ence: MEC/10/06/055).
3. Results
A potential cohort of 515,455 simvastatin userswas identiﬁed by the
Ministry of Health. A very small proportion of these linked records
(0.3%, n = 1761) were excluded because the dispensing information
and health data clearly did not refer to the same person. Another
200,142 patients were excluded because they were dispensed simva-
statin between 1 January and 30 April 2005. The study cohort thereforeTable 1
Characteristics of cases and controls. Values are numbers (percentages) unless stated otherwis
Characteristic Rhabdomyolysis
Cases
(n = 29)
Mean age (SD) 66.7 (14.0)
Female sex 11 (37.9)
Ethnicity
Māori 4 (13.8)
Paciﬁc 5 (17.2)
European 16 (55.2)
Asian 3 (10.3)
Other –
Missing 1 (3.5)
NZ Dep06 quintile
1 (least disadvantaged) 1 (3.5)
2 5 (17.2)
3 5 (17.2)
4 7 (24.1)
5 (most disadvantaged) 11 (37.9)
Missing –
Hospital admissions
Ever admitted with a diagnosis of:
Coronary artery disease 9 (31.0)
Type 2 diabetes 8 (27.6)
Renal impairment or failure 6 (20.7)
Admitted in 30 days before index date for any reason 1 (3.5)
Admitted in 30 days before index date with a diagnosis of:a
Myocardial infarction –
Type 2 diabetes 1 (3.5)
Renal impairment or failure –
At least one cancer diagnosis in cancer registry 2 (6.9)
Dispensed medicines in 30 days before index dateb
Amiodarone –
Azol antifungals 1 (3.5)
Calcium channel blockers 10 (34.5)
Cyclosporin 2 (6.9)
Fibrates 1 (3.5)
Macrolide antibiotics 3 (10.3)
Thiazolidinediones/glitazones 1 (3.5)
Warfarin 5 (17.2)
a No cases or controls were admitted with conditions related to excess alcohol consumption
ma, hepatic impairment or failure, hypothyroidism, or Type 1 diabetes.
b No cases or controls were dispensed danazol, fusidic acid, nefazodone, nicotinic acid, or pr
c Fisher's exact.included 313,552 patientswho initiated simvastatin use between 1May
2005 and 31 December 2009.
A total of 136 potential cases were identiﬁed from the study cohort
using the diagnostic criteria in Appendix 2; 29 met the case deﬁnition
for rhabdomyolysis (three fatal, all inpatients). A further 14 were classi-
ﬁed as deﬁnite (n = 3) or possible (n = 11) myopathy. The character-
istics of cases and their controls are shown in Table 1; data are provided
separately for cases with rhabdomyolysis and their controls, and for all
cases (rhabdomyolysis or myopathy) and controls combined. The
following ﬁndings relate to rhabdomyolysis cases and their controls.
The mean age of both cases and controls was 66.7 years and 37.9%
were female. Cases were more likely than controls to be of Māori,
Paciﬁc, or Asian ethnicity and were more likely to belong to the most
disadvantaged socio-economic quintile, and to have ever been admitted
to hospital with a diagnosis of coronary artery disease (myocardial
infarction or angina), Type 2 diabetes, or renal impairment or failure.
Two controls were admitted to hospital in the 30 days before the
index date with a diagnosis of myocardial infarction; no cases or
controls were admitted during that period with any other diagnoses
associated with an increased risk of rhabdomyolysis. Cases were more
likely than controls to be current users of calcium channel blockers,
cyclosporin, macrolide antibiotics, and warfarin.
Table 2 shows the results of the primary analysis. Twenty one
(72.4%) of the 29 rhabdomyolysis cases were current users of 40 mg
simvastatin daily and ﬁve (17.2%) were using 20 mg daily; the corre-
sponding ﬁgures for their controls were 65 (22.4%) and 110 (37.9%)e.
p-Value Rhabdomyolysis or myopathy p-Value
Controls
(n = 290)
Cases
(n = 43)
Controls
(n = 430)
66.7 (13.7) 1.0 65.7 (13.9) 65.7 (13.7) 1.0
110 (37.9) 1.0 14 (32.6) 140 (32.6) 1.0
0.137 0.004
26 (9.0) 6 (14.0) 36 (8.4)
16 (5.5) 8 (18.6) 20 (4.7)
207 (71.4) 25 (58.1) 308 (71.6)
19 (6.6) 3 (7.0) 30 (7.0)
2 (0.7) – 2 (0.5)
20 (6.9) 1 (2.3) 34 (7.9)
0.180 0.350
48 (16.6) 3 (7.0) 68 (15.8)
56 (19.3) 7 (16.3) 84 (19.5)
46 (15.9) 8 (18.6) 76 (17.7)
78 (26.9) 11 (25.6) 109 (25.4)
62 (21.4) 14 (32.6) 92 (21.4)
– – 1 (0.2)
68 (23.5) 0.363 15 (34.9) 98 (22.8) 0.067
38 (13.1) 0.034 12 (27.9) 55 (12.8) 0.007
14 (4.8) 0.001 10 (23.3) 19 (4.4) b0.001
8 (2.8) 0.581c 3 (7.0) 12 (2.8) 0.135
2 (0.7) 1.0c 1 (2.3) 3 (0.7) 0.426c
2 (0.7) 0.249c 2 (4.7) 2 (0.5) 0.043c
1 (0.3) 1.0c – 1 (0.2) 1.0c
22 (7.6) 0.893c 3 (7.0) 41 (9.5) 0.582
2 (0.7) 1.0c 1 (2.3) 3 (0.7) 0.318c
– 0.091c 1 (2.3) – 0.091c
53 (18.3) 0.049 13 (30.2) 80 (18.6) 0.067c
2 (0.7) 0.043c 2 (4.7) 2 (0.5) 0.043c
9 (3.1) 1.0c 1 (2.3) 14 (3.3) 1.0c
4 (1.4) 0.019c 5 (11.6) 7 (1.6) 0.002c
– 0.091c 1 (2.3) – 0.091c
15 (5.2) 0.011 7 (16.3) 18 (4.2) 0.001
or illicit drug use, overdose, hypothermia, hyperthermia, epilepsy, extreme exertion, trau-
otease inhibitors.
Table 2
Risk of rhabdomyolysis, and rhabdomyolysis or myopathy, resulting in hospitalisation or death in relation to daily dose of simvastatin.
Cases (no [%]) Controls (no [%]) Unadjusted matched odds ratio
(95% CI)
Adjusted matched odds ratioa
(95% CI)
Rhabdomyolysis (n = 29) (n = 290)
Current user of simvastatin
10 mg – 16 (5.5) – –
20 mg 5 (17.2) 110 (37.9) 1.0 1.0
40 mg 21 (72.4) 65 (22.4) 7.0 (2.5–19.5) 5.3 (1.9–15.0)
60 mg – 6 (2.1) – –
80 mg – 10 (3.5) – –
Recent user of simvastatin – 17 (5.9) – –
Past user of simvastatin 3 (10.3) 66 (22.8) – –
Rhabdomyolysis or myopathy (n = 43) (n = 430)
Current user of simvastatin
10 mg 1 (2.3) 29 (6.7) – –
20 mg 11 (25.6) 153 (35.6) 1.0 –
40 mg 26 (60.5) 94 (21.9) 3.9 (1.8–8.2) –
60 mg – 7 (1.6) – –
80 mg – 12 (2.8) – –
Recent user of simvastatin – 31 (7.2) – –
Past user of simvastatin 5 (11.6) 104 (24.2) – –
a Adjusted for NZDep06quintile and a history of ever being admitted to hospitalwith a diagnosis of renal failure or impairment. Adjusted odds ratios are not presented for the combined
rhabdomyolysis or myopathy analysis as adjustment for covariates did not change the estimate by more than 10%.
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dailywere seven times as likely to develop rhabdomyolysis as those tak-
ing 20 mg daily; the odds ratio was 7.0 (95% CI 2.5–19.5). This risk was
attenuated somewhat after adjusting for socio-economic position and a
history of renal failure or impairment; the adjusted odds ratio was 5.3
(95% CI 1.9–15.0). Further adjustment for other potential confounders
(including ethnicity; hospital admission at any time before the index
date with coronary artery disease or with diabetes; admission
≤30 days before the index date for any reason or with acutemyocardial
infarction; and current use of amiodarone, calciumchannel blockers, cy-
closporin, macrolide antibiotics, or warfarin) had no material impact.
In the analysis based on all cases and controls, current users of
40 mg simvastatin daily were four times as likely as users of 20 mg
to develop rhabdomyolysis or myopathy. The unadjusted odds ratio
was 3.9 (95% CI 1.8–8.2); adjustment for potential confounders had
a negligible impact on this estimate. There were no cases using
80 mg daily, so the risk associated with this dose could not be exam-
ined. No cases or controls were taking simvastatin in combination
with ezetimibe.
The overall number of cases, and the small number of cases and con-
trols using medicines known to interact with simvastatin, limited our
ability to explore effect modiﬁcation by concomitant drug use. In an
analysis which included an interaction term for current use of calciumTable 3
Absolute risk of rhabdomyolysis, and rhabdomyolysis or myopathy, resulting in hospitalisation
Number of cases Perso
Rhabdomyolysis (n = 26)
Daily dose of simvastatin
20 mg 5 243,6
40 mg 21 183,0
Rhabdomyolysis or myopathy (n = 38)
Daily dose of simvastatin
10 mg 1 57,6
20 mg 11 243,6
40 mg 26 183,0
a In total therewas an estimated 511,076 person-years of use of simvastatin alone (not in com
for 50 mg, 5299 for 60 mg, 16 for 70 mg, and 19,331 for ≥80 mg simvastatin daily. There werchannel blockers (Supplemental Table 1), the odds ratios were consis-
tent with effect modiﬁcation, however, we could not exclude chance
as an explanation for this ﬁnding. The adjusted odds ratios for rhabdo-
myolysis were 10.8 (95% CI 1.2–94.5) for current users of calcium chan-
nel blockers and 3.9 (95% CI 1.2–12.9) for non-users of those drugs; the
interaction odds ratio was 2.8 (95% CI 0.2–32.7).
In total, one case and 24 controls who were past or recent users of
simvastatin were current users of atorvastatin. In a secondary analysis,
current users of 40 mg simvastatin or 20 mg atorvastatin were about
six times as likely to develop rhabdomyolysis as current users of
20 mg simvastatin or 10 mg atorvastatin (adjusted odds ratio 5.7, 95%
CI 2.0–15.8). The corresponding odds ratio for rhabdomyolysis andmy-
opathy combined was 3.5 (95% CI 1.7–7.4).
In the study cohort there was an estimated total of 756,627 person-
years of follow-up, which included 511,076 person-years of use of sim-
vastatin alone and 1007 person-years of use of simvastatin in combina-
tion with ezetimibe. The crude incidence rates of rhabdomyolysis by
daily dose of simvastatin are shown in Table 3. The rate in users of
20mgwas 2.1 (95% CI 0.7–4.8) per 100,000 person-years, while the cor-
responding rate in users of 40 mg was almost six times higher at 11.5
(95% CI 7.1–17.5). A dose–response relationship was also found for
rhabdomyolysis and myopathy combined; the incidence rates per
100,000 person-years for daily doses of 10 mg, 20 mg, and 40 mgor death in relation to daily dose of simvastatin in current users.
n-years of exposurea Crude incidence rate per 100,000 person-years
(95% CI)
59 2.1 (0.7–4.8)
72 11.5 (7.1–17.5)
09 1.7 (0.04–9.7)
59 4.5 (2.3–8.1)
72 14.2 (9.3–20.8)
binationwith ezetimibe); person-years not shown in the tablewere 1879 for 30 mg, 211
e 1007 person-years of use of simvastatin with ezetimibe.
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9.3–20.8) respectively.
Eight of the 26 (30.8%) cases of rhabdomyolysis who were current
users of simvastatin had been reported to CARM; two other cases with
myopathy were also reported. We did not ﬁnd any eligible cases in
the CARM database which our study methods had failed to identify.
4. Discussion
4.1. Principal ﬁndings
In this large population-based study of simvastatin initiators, current
users of 40mg simvastatin dailywere about ﬁve times as likely to be ad-
mitted to hospital with, or die from, rhabdomyolysis as those taking
20 mg. The matched odds ratio (adjusted for socio-economic position
and a history of renal failure or impairment) in the case–control analysis
was 5.3 (95% CI 1.9–15.0). The absolute excess risk of rhabdomyolysis
associated with the use of the higher dose of simvastatin was about 10
per 100,000 person-years; the crude incidence rates in current users
of 20 mg and 40 mg were 2.1 (95% CI 0.7–4.8) and 11.5 (95% CI
7.1–17.5) per 100,000 person-years respectively.
4.2. Strengths and limitations
This study had several strengths and some limitations which war-
rant discussion. The use of the Pharms database as a source of informa-
tion about drug exposure had several advantages. First, the database
contains records of subsidised dispensings of drugs for the entire popu-
lation of NewZealand.Moreover, it is highly likely that these records are
complete since pharmacists are not remunerated for such dispensings
unless they submit a claim. Second, the inclusion of an NHI with nearly
all simvastatin dispensings (increased from 91.5% in 2005 to 99.1% in
2009) meant we could identify almost all users of simvastatin during
the study period, obtain information about their use of other drugs,
and link to their hospital discharge andmortality data. Third, Pharms re-
cords relate to drugs that were actually dispensed (not simply pre-
scribed) to patients. However it is still impossible to know whether
every patient took their medicines as directed, though the impact of
substantial non-adherence (particularly if it increased with increasing
doses of simvastatin because higher doses of simvastatinwere, in gener-
al, less well tolerated) would be to underestimate the risks of rhabdo-
myolysis and myopathy in users of higher doses of simvastatin.
To avoid the bias that can arise from the inclusion of prevalent users
(i.e. patients already taking simvastatin at the beginning of the studype-
riod whomight carry a different risk of rhabdomyolysis, and be taking a
different dose, from those who started the drug during the study peri-
od) [29], we restricted the study cohort to those patients who initiated
a new episode of simvastatin use during the study period. We cannot
entirely rule out the possibility that we inadvertently included some
prevalent users in the cohort (because of the incomplete NHI coverage
in 2005); however, the proportion would be extremely small and
should not have distorted our ﬁndings.
Case ascertainment is a further strength of our study. All members of
the study cohortwhowere admitted to hospitalwith rhabdomyolysis or
myopathy during the study period are likely to have been identiﬁed
using the National Minimum Dataset, since public and private hospitals
are required to report all inpatient and day patient discharges and re-
cord diagnoses according to strict ICD coding standards [30]. Similarly,
cause of death coding in theMortality Collection is subject to ICD coding
conventions and the quality of such coding was recently found to be
very good [31]. Our review of the spontaneous reports of rhabdomyoly-
sis and myopathy in statin users which were received by CARM also
provided reassurance about the likely completeness of case ascertain-
ment. We validated the diagnosis of rhabdomyolysis and myopathy by
reference to hospital discharge letters and death records using standard
criteria. For a minority of patients, these sources did not provide CKconcentrations. However, for all ﬁve rhabdomyolysis cases (one fatal)
without recorded CK levels a clinical diagnosis of rhabdomyolysis had
been made and there was documented evidence of acute renal failure.
Referral bias is unlikely to have played a role in our study, as the serious
nature of rhabdomyolysis is such that patients are likely to have been
referred to hospital regardless of the dose of simvastatin they were, or
were not, taking.
We took the date of diagnosis as the index date because the precise
date of onset of muscle symptoms was not known for all cases. Poten-
tially this could have led to amisclassiﬁcation of exposure status, andbi-
ased estimates of relative risk, if a gradual onset of symptoms had led to
an early discontinuation of simvastatin or a reduction in dose. However,
this does not appear to have been a substantive issue; of the rhabdomy-
olysis cases who were classiﬁed as current users, only three were dis-
pensed a different dose of simvastatin in the 90 day period before the
index date (a reduction in dose from 80 mg to 40 mg [32 days before
index date], a short-term reduction from 40 mg to 20 mg [57 days be-
fore index date, resumed 40 mg 20 days later], and an increase from
20 to 40 mg [51 days before index date]). Moreover, the three rhabdo-
myolysis cases whowere past users (including the current user of ator-
vastatin) stopped simvastatin well before the index date (155 days,
16 months, 24 months).
Confounding is also unlikely to have had a substantive impact on the
results of the case–control analysis; controls were matched to cases by
age and sex, most of the relevant risk factors for rhabdomyolysis were
identiﬁable using hospital discharge and dispensing data, and we ex-
plored potential confounding by concomitant medicine use and other
risk factors for rhabdomyolysis in a matched analysis. As would be ex-
pected on the basis of clinical guidelines, cases and controls who had a
history of hospital admission with coronary artery disease at cohort
entryweremore likely to have been started on higher doses of simvastat-
in than patientswithout such histories; a similar, but lessmarked, pattern
was seen for both renal impairment or failure and diabetes (Supplemen-
tal Table 2). Caseswere alsomore likely than controls to have been admit-
ted with these conditions at any time before the index date (Table 1).
However, adjusting for a history of coronary artery disease and diabetes
did not change the odds ratios, and we adjusted for a history of renal im-
pairment or failure.Hence, confoundingby these co-morbidities is unlike-
ly to explain the strong associations we observed.
We did not have information about the use of over-the-counter or
unsubsidised drugs. However, the drugs which are known or suspected
to increase the risk of rhabdomyolysis are prescription-only and
subsidised in NewZealand; hence their dispensing by community phar-
macies would have been identiﬁed. Any inpatient use of such drugs
would not have been detected, although just one patient with rhabdo-
myolysis and eight matched controls were admitted to hospital in the
30 days before the index date. Finally, we did not have information
about some lifestyle factorswhich have been associatedwithmuscle in-
jury in statin users (consumption of grapefruit or cranberry juice, low
body mass index) [23], but any uncontrolled confounding by these fac-
tors would be insufﬁcient in magnitude to explain the observed excess
risk in users of 40 mg simvastatin.
Although our study is the largest investigation to date of serious
muscle injury in a general population of simvastatin users, it had insuf-
ﬁcient power to explore effect modiﬁcation by concomitant medicine
use, or by ethnicity. Nor could we examine effect modiﬁcation by vari-
ants in the SLCO1B1 gene which are associated with a higher risk of
statin-related adversemuscle events [32]. The small number of rhabdo-
myolysis cases is also reﬂected in the wide 95% conﬁdence interval for
the primary analysis, although the lower bound indicates at least a dou-
bling of risk associated with the use of 40mg versus 20mg simvastatin.
Finally, we studied muscle events which were severe enough to re-
sult in hospitalisation and/or death. The exclusion of less severe myop-
athy (which would be managed in general practice) means that the
overall rates of symptomaticmuscle injury in simvastatin users are like-
ly to be considerably higher than those reported here.
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None of the longer-term randomised controlled trials involving sim-
vastatin [8–12] directly compared outcomes in users of 40mg versus 20
mg daily, hence no trial-based estimates of relative or excess absolute
risk of rhabdomyolysis exist for these doses. Moreover, the very small
number of exposed cases in the 40 mg (5 cases in the Heart Protection
Study [11]) and 20 mg (3 cases in IDEAL [12], 1 in 4S [10], none in
SEARCH [8] or A to Z [9]) groups of these trials did not permit the esti-
mation of stable incidence rates. However, our results are consistent
with the ﬁndings of an observational study which used data from
the Group Health Cooperative [13]. In that study, based on 29 validated
cases of rhabdomyolysis (deﬁned using a lower CK threshold than ours
of ≥10 times the upper limit of normal) and 170,605 person-years of
simvastatin use, an almost 3-fold higher incidence of rhabdomyolysis
was found in patients who were prescribed 40–79 mg simvastatin
daily in the three months before diagnosis versus those prescribed
20–39 mg daily; the incidence rates were 14.1 (95% CI 6.1–27.8) and
5.3 (95% CI 1.5–13.6) per 100,000 person-years respectively. Converse-
ly, no clear dose–response relationship was found in a UK general prac-
tice records-based cohort study which included 159,790 simvastatin
users; relative to non-users, the reported hazard ratios for myopathy
or rhabdomyolysis (deﬁned as a recorded diagnosis in the general prac-
tice records of either condition or CK≥ 4 times upper limit of normal) in
users of 40 or 80 mg simvastatin and users of 10 or 20 mg were very
similar [33]. Incidence rates for the twodose categorieswere not report-
ed. Other population-based investigations of muscle injury in patients
taking statins also included fewer simvastatin users and person-years
of exposure than the present study, and did not provide relative risks
or estimates of rhabdomyolysis incidence by simvastatin dose [27,
34–40]. Our study therefore adds to current knowledge by presenting,
for the ﬁrst time, separate risk estimates for 20 mg and 40 mg
simvastatin.
A recent Canadian cohort study found a higher risk of hospitalisation
with rhabdomyolysis in statin users who were co-prescribed clarith-
romycin or erythromycin in the preceding 30 days [41]. Owing to the
small numbers, we were unable to test for this interaction in our
study. We did, however, undertake a sensitivity analysis conﬁned to
cases and controls who had not taken macrolide antibiotics in the
30 days before the index date; a signiﬁcantly higher risk of rhabdomyol-
ysis in current users of 40 mg versus 20 mg simvastatin was still ob-
served (data not shown).
Our observation that some cohort members stopped and restarted,
or completely discontinued, simvastatin use during the study period
(non-use accounted for about a third of follow-up time) is consistent
with the ﬁndings of another New Zealand study which examined statin
adherence following an acute coronary event [42].
The pathophysiological mechanism bywhich statins induce myopa-
thy and rhabdomyolysis is still to be elucidated [43]. Postulated mecha-
nisms include cellular oxidative stress, derangement of mitochondrial
function andmuscular calciumhomeostasis, inﬂammatory, and autoim-
mune reactions [43].
4.4. Conclusion and clinical implications
Recent meta-analyses of individual patient data by the Cholesterol
Treatment Trialists' Collaboration have shown that the beneﬁts of statin
use far outweigh any serious adverse events, even in patients with low
predicted cardiovascular disease risk [3,4,44]. The data regarding rhab-
domyolysis risk were sparse and were based on highly selected trial
participants; [3] hence they are not necessarily generalisable to broader
groups of statin users.Moreover, regularmonitoring of CK levels in trials
(which is not recommended in clinical practice) [14,15] can result
in fewer cases of muscle injury than otherwise would have occurred
if asymptomatic participants with elevated CK levels had not
discontinued statin use [8]. The present study provides reassuringevidence that the incidence of rhabdomyolysis in a general population
of simvastatin users is very low. Nonetheless, our observation of a
higher risk associated with the use of 40 mg versus 20 mg simvastatin
daily has potential implications for clinical practice— particularly in set-
tingswhere simvastatin is recommended as the statin of choice. Current
guidelines in the UK [14] and New Zealand [15], for example, recom-
mend simvastatin at a dose of 40 mg daily as the ﬁrst-line regimen for
secondary prevention of cardiovascular events as well as primary pre-
vention in patients with ≥20% 10-year (UK) or N20% 5-year (NZ) pre-
dicted absolute risk. Our ﬁndings, therefore, raise two important
questions. Is an excess rhabdomyolysis risk of about 10 per 100,000
person-years in users of 40 mg versus 20 mg simvastatin acceptable in
view of the beneﬁts of more intensive statin therapy? If not, what is
the optimal statin regimen (which statin, which dose) to achieve
the largest possible reduction in LDL cholesterol, while at the same
time avoiding a potentially unnecessary excess risk of seriousmuscle in-
jury? These questions are especially pertinent in light of the recently
demonstrated beneﬁts of statin use in patients with a 5-year predicted
cardiovascular risk b10% and the ensuing debate over a suggestion
that clinical guidelines be revised to offer statin therapy to this group
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